IT - EN HOME WHO WE ARE PHARMACEUTICAL BUSINESS RARE DISEASES INVESTORS CORPORATE GOVERNANCE PRESS RELEASES AND NOTICES PARTNERING CAREERS INTERNATIONAL PRESENCE Recordati offers a wide range of innovative drugs mainly in the cardiovascular and urological pathologies sectors, as well as unique treatments for rare diseases. Last News ERYTECH submits EMA Marketing Authorization Financial news and new initiatives Who we are Recordati is an established international pharmaceutical group, partner of important companies. >> Rare Diseases Every patient with a rare disease has the right to the best possible treatment. >> Research and Development With an eye to the future, the Recordati Group makes substantial investments in research and development. >> International presence Recordati in the world, an international development strategy. >> Partnering Impegnati da sempre nella creazione di valore futuro attraverso un’accorta politica di alleanze >> Il Titolo Recordati - Investors “La divisa più preziosa nei mercati finanziari è l’informazione affidabile”. (Michael Bloomberg, Mary Shapiro) >> Bilancio Annuale Brochure Istituzionale The Prize Servizio Alert Dati societari Recordati S.p.A. via M. Civitali 1, 20148 Milano, Italia Capitale sociale Euro 26.140.644,5 i.v. Reg.Imp.Milano/Codice Fiscale/P.Iva 00748210150 REA Milano n. 401832 delivered by Tech Style Servizi Sito Servizio di Alert Note Legali Privacy Policy Ultime notizie 14 settembre 2015 ERYTECH submits EMA Marketing Authorization 8 settembre 2015 ORPHAN EUROPE Announces that Health Canada has Granted Market Authorization for Carbaglu® (carglumic acid)